Last reviewed · How we verify
Rabivax-S
Rabivax-S is a recombinant rabies virus vaccine that stimulates immune responses against rabies virus through viral glycoprotein antigens.
Rabivax-S is a recombinant rabies virus vaccine that stimulates immune responses against rabies virus through viral glycoprotein antigens. Used for Rabies post-exposure prophylaxis, Rabies pre-exposure prophylaxis.
At a glance
| Generic name | Rabivax-S |
|---|---|
| Sponsor | University of Oxford |
| Drug class | Rabies vaccine |
| Target | Rabies virus glycoprotein |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | FDA-approved |
Mechanism of action
Rabivax-S is a live attenuated or recombinant rabies vaccine developed to provide immunization against rabies virus infection. It works by presenting rabies virus antigens (particularly the glycoprotein) to the immune system, triggering both cellular and humoral immune responses that provide protection against rabies virus exposure. The vaccine is designed for post-exposure prophylaxis or pre-exposure immunization.
Approved indications
- Rabies post-exposure prophylaxis
- Rabies pre-exposure prophylaxis
Common side effects
- Local injection site reactions (pain, erythema, swelling)
- Fever
- Myalgia
- Headache
Key clinical trials
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults (PHASE2)
- A Comparison of Safety and Immunogenicity of Rabies Pre Exposure Prophylaxis Regimen Between Gvt of India Approved and WHO Approved. (PHASE3)
- Safety and Immunogenicity of the Inactivated Rabies Vaccine RABIVAX-S Administered Intramuscularly and Intradermally (PHASE4)
- Non-specific Effects of Rabies Vaccine (PHASE4)
- Safety of Rabivax-S for Pre-exposure Prophylaxis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rabivax-S CI brief — competitive landscape report
- Rabivax-S updates RSS · CI watch RSS
- University of Oxford portfolio CI